Reuters
19 Nov 2026, 21:49 UTC · 54m ago
Bausch + Lomb eye-drop drug misses mid-stage study main goal
Impact · against what's priced in
The failure of Bausch + Lomb's mid-stage eye-drop study represents a setback for its pipeline growth. This negative outcome likely triggers downward revisions for forward growth expectations.
- BLCO−0.40
No priced-in read yet
- In context
The drug's failure to meet its primary goal in a mid-stage study reduces the probability of future commercialization and expected revenue growth from this specific asset.
Read from the article alone
- Actual

Top 1 mover · tap to explore




